Search for content, post, videos

Hemispherian forms a Clinical Advisory Board

Board meeting

Hemispherian has announced the formation of its Clinical Advisory Board (CAB) by appointing world leaders in brain cancer.

The advisory board will provide external advice, guidance, and support to the company, shaping the continuing preclinical and clinical development of the GLIX family of anticancer pharmaceuticals, states the company in a press release.

“I am thrilled that Dr Roger Stupp, Dr Michael Lim, Dr Monika Hegi and Dr Einar Vik-Mo have joined the Hemispherian Clinical Advisory Board,” says Adam Robertson, Hemispherian’s Chief Scientific Officer. “Their important and unique expertise will contribute greatly to Hemispherian’s work to improve and extend the lives of people living with cancer by helping advance the company’s novel class of small molecule drugs (GLIX) into clinical trials.”

Roger Stupp – Chairman

Chairman is Dr Roger Stupp, Chief of Neuro-Oncology in the Department of Neurology and Paul C Bucy Professor of Neurological Surgery at Northwestern University Chicago. His clinical interests include the multimodality management of primary and secondary brain tumors, head and neck tumors, and lung cancers, as well as new drug development and the association of chemotherapy and radiation therapy. Stupp’s work has repeatedly led to the establishment of a new standard of care for newly diagnosed glioblastoma, namely he was instrumental in developing and establishing the combination of temozolomide and radiotherapy, and more recently, for the clinical development of Tumor Treating Fields in brain tumors.

“I am excited to provide advice and guidance to the Hemispherian team,” says Roger Stupp. “The preclinical data is encouraging and forms the foundation for advancing preclinical and later clinical studies.”

Einar O. Vik-Mo, Michael Lim and Monika Hegi

Members of the CAB are Dr. Michael Lim, Chairman of the Department of Neurosurgery at Stanford University, Dr. Monika Hegi Head of the Laboratory of Brain Tumour Biology and Genetics at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, and Dr. Einar O. Vik-Mo, Head of the Surgical Neuro-Oncology section at Oslo University Hospital.

Einar O. Vik-Mo is a member of the Norwegian Cancer Society’s brain cancer expert group. He has PhD training in tumor cell biology and immunotherapy, and is the principal investigator on several early phase studies on innovative therapies. His main surgical focus is on malignant brain tumors, intraoperative imaging and monitoring.

“Hemispherian’s lead pharmaceuticals show great promise in precision glioblastoma multiforme treatment,” says Einar Vik-Mo. “Hemispherian’s ongoing collaboration with the Vilhelm Magnus Laboratory at Oslo University Hospital will refine their targeted approach to treating glioblastoma multiforme.”

Michael Lim is a board-certified neurosurgeon specializing in brain tumors and trigeminal neuralgia. He has extensive clinical experience in treating brain tumors by deploying the most advanced surgical techniques. In addition Lim has experience in developing novel therapies and advancing these pharmaceuticals into the clinic.

Monika Hegi is the recipient of numerous awards including the Victor Levin for Neuro-Oncology research. She specializes in the identification of predictive factors in therapeutic response and in the exploration of novel druggable targets. Hegi’s research focuses on glioma epigenetics, molecular mechanisms of gliomas, and translational research.

Photo: iStock